IRIS
LEMOLI, ROBERTO MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 21.454
Totale 21.454
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 21.454
Totale 21.454
Salva come PNG Salva come JPEG
Città #
Genova 16.750
Rapallo 2.509
Genoa 2.056
Vado Ligure 78
Bordighera 61
Totale 21.454
Salva come PNG Salva come JPEG
Nome #
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 166
T cell alloreactivity induced by normal G-CSF-mobilized CD34+ blood cells. 142
Viability of autologous bone marrow. 140
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. 133
Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes 133
Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies. 132
The sixth sense: hematopoietic stem cells detect danger through purinergic signaling. 130
T lymphocyte killing by a xanthine-oxidase-containing immunotoxin. 129
The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System 129
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients 129
Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. 128
Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes 128
Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. 127
The P2X7 receptor: a key player in IL-1 processing and release. 127
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis 126
The CD47 pathway is deregulated in human immune thrombocytopenia. 124
Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma 123
C-kit ligand (SCF) in human multiple myeloma cells. 119
Combined use of growth factors to stimulate the proliferation of hematopoietic progenitor cells after autologous bone marrow transplantation for lymphoma patients. 119
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. 118
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 118
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 118
Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. 117
Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies. 117
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives 117
Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells 116
Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study. 115
CD103 Marks a Subset Of Human CD34+-Derived Langerin+ Dendritic Cells Which Induce T Regulatory Cells Via Indoleamine 2,3-Dioxygenase-1. 115
Selection and transplantation of autologous hematopoietic CD34+ cells for patients with multiple myeloma. 114
Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. 114
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia 114
Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma. 113
Interleukin-9 stimulates the proliferation of human myeloid leukemic cells. 113
Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. 113
Cryopreserved autologous bone marrow transplantation in patients with acute nonlymphoid leukemia: chemotherapy before harvesting is the main factor in delaying hematological recovery. 113
Generation and functional characterization of human dendritic cells derived from CD34 cells mobilized into peripheral blood: comparison with bone marrow CD34+ cells. 112
Harnessing NK Cells for Cancer Treatment 112
Sensitivity of chronic myeloid leukemia hemopoietic progenitors to PTT-119 in combination with human recombinant interferon alpha and gamma. 111
Characterization of autotransplant-related thrombocytopenia by evaluation of glycocalicin and reticulated platelets. 110
Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study. 110
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 110
European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. 110
In vitro growth of myeloma cells. 109
Purging in autologous and allogeneic bone marrow transplantation. 109
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation. 109
The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling 109
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 109
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 108
Megakaryocyte progenitors derived from bone marrow or G-CSF-mobilized peripheral blood CD34 cells show a distinct phenotype and responsiveness to interleukin-3 (IL-3) and PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF). 108
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. 108
Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. 108
Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: A GITMO survey on 809 patients autografted in first complete remission 108
Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. 107
Positive selection and transplantation of autologous highly purified CD133(+) stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging. 107
Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: A phase I clinical trial 107
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. 106
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia. 106
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 106
Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. 106
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach 106
Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells. 105
Pharmacological elimination of tumor cells contaminating normal human bone marrow using PTT-119. 105
Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia. 105
Interleukin-9 in human myeloid leukemia cells. 104
Impaired dendritic cell immunophenotype and function in heart transplant patients undergoing active cytomegalovirus infection. 104
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. 104
Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients 104
Improvement of human myeloma stem cell growth in a liquid culture system supplemented with phytohemagglutinin. 104
The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. 104
Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. 104
Stem cell plasticity: time for a rappraisal? 103
Newer options for treating drug-resistant (MDR+) cancer cells using photoradiation therapy. 103
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 103
The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling 103
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. 103
Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis 102
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 102
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 102
FLAG (fludarabine+cytosine arabinoside+G-CSF) induces complete remission in acute-phase chronic myeloid leukaemia: a case report. 101
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 101
A novel model of CCl4-induced cirrhosis with ascites in the mouse. 101
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies 101
Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas 101
Gpr171, a putative P2Y-like receptor, negatively regulates myeloid differentiation in murine hematopoietic progenitors. 101
Interleukin-11 induces Th2 polarization of human CD4(+) T cells. 100
Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. 99
Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemia 99
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 98
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 98
Selective expansion of normal haemopoietic progenitors from chronic myelogenous leukaemia marrow. 97
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. 96
Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34- human stem cells. 96
Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. 96
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 96
Extracellular ATP exerts opposite effects on activated and regulatory CD4+ T cells via purinergic P2 receptor activation. 96
Adoptive Cell Therapy and Immune Check Points Inhibitors As a Salvage Treatment for Patient Affected By Relapsed/Refractory Hodgkin's Lymphoma 96
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience. 95
Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. 95
Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. 95
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. 95
Totale 11.057
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.933
article - articoli 59.717
book - libri 0
conference - conferenze 226
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 990
Totale 121.866
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.740 0 145 309 400 449 574 905 428 586 1.010 599 335
2020/20211.750 110 127 143 141 137 166 126 182 164 202 99 153
2021/20222.954 57 121 67 360 234 231 233 647 111 287 80 526
2022/20233.153 357 283 69 360 478 527 5 269 489 31 227 58
2023/20241.479 66 181 72 166 110 280 99 148 77 29 79 172
2024/2025115 65 50 0 0 0 0 0 0 0 0 0 0
Totale 21.794